First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Immunic: the story is balanced — CALLIPER Phase 3 trial interim analyses and primary endpoint readout for vidofludimus calcium in relapsing-remitting MS…
★ Analysts see FY2027 revenue reaching $13M — +0.0% growth in a single year.
What Moves the Stock
1CALLIPER Phase 3 trial interim analyses and primary endpoint readout for vidofludimus calcium in relapsing-remitting MS (expected 2026-2027 based on enrollment timelines)
2ENSURE Phase 3 trial enrollment progress and data readouts for progressive MS indication
3IMU-856 Phase 2 data in ulcerative colitis showing efficacy on endoscopic endpoints and safety profile versus existing JAK inhibitors
4Partnership announcements or licensing deals with major pharmaceutical companies for ex-US rights or specific indications
5Equity financing announcements (dilution risk given negative operating cash flow and limited runway)
6FDA/EMA regulatory feedback on trial designs or breakthrough therapy designation applications
7No current revenue - pre-commercial stage
8Future potential: vidofludimus calcium royalties/sales in MS indication (estimated peak sales $500M-$1B+ if approved)
growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds…
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (vidofludimus calcium…
Watch on earnings: CALLIPER trial enrollment completion and event-driven timeline to primary endpoint (annualized relapse rate reduction), Cash and cash equivalents balance versus quarterly operating cash burn trend, IMU-856 Phase 2 endoscopic remission rates in ulcerative colitis versus historical placebo rates (15-20% baseline).
One Sentence Summary:
Immunic: the story is balanced — calliper phase 3 trial interim analyses and primary endpoint readout for vidofludimus calcium in relapsing-remitting ms (expected 2026-2027.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.